Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

Current Oncology Reports

Issue 5/2005

Content (11 Articles)

Editor’s Commentary

The patient and web-based cancer information: A role for provider input into this rapidly evolving relationship

Timothy M. Markman, Maurie Markman

Web alert

Advances in the molecular genetics of acute leukemia

Joseph M. Scandura

Advances in the treatment of chronic lymphocytic leukemia

Nicole Lamanna

Immunotherapy for acute myeloid leukemia

Joseph G. Jurcic

Linking KSHV to human cancer

Emily L. Wong, Blossom Damania

Diffuse large B-cell lymphomas with plasmablastic differentiation

Julie Teruya-Feldstein

New developments in immunotherapy for non-Hodgkin’s lymphoma

John P. Leonard, Richard R. Furman, Jia Ruan, Morton Coleman

Clinical Trials Report

Kim Margolin

Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management

Nicole Kounalakis, James S. Goydos

Immunotherapy for melanoma: The good, the bad, and the future

Christian H. Poehlein, Dominik Rüttinger, Jun Ma, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox

Aug 05
Issue: 4/2005
Dec 05
Issue: 6/2005

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits